Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $57

Benzinga · 1d ago
Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $62 to $57.